Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

Lizza E. L. Hendriks*, Gerben Bootsma, Jean Mourlanette, Clemence Henon, Laura Mezquita, Roberto Ferrara, Clarisse Audigier-Valette, Julien Mazieres, Corentin Lefebvre, Boris Duchemann, Sophie Cousin, Cecile le Pechoux, Angela Botticella, Dirk De Ruysscher, Anne-Marie C. Dingemans, Benjamin Besse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)182-189
Number of pages8
JournalEuropean Journal of Cancer
Volume116
DOIs
Publication statusPublished - Jul 2019

Keywords

  • NSCLC
  • Immune checkpoint inhibition
  • Leptomeningeal metastases
  • NIVOLUMAB

Cite this

Hendriks, L. E. L., Bootsma, G., Mourlanette, J., Henon, C., Mezquita, L., Ferrara, R., Audigier-Valette, C., Mazieres, J., Lefebvre, C., Duchemann, B., Cousin, S., le Pechoux, C., Botticella, A., De Ruysscher, D., Dingemans, A-M. C., & Besse, B. (2019). Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. European Journal of Cancer, 116, 182-189. https://doi.org/10.1016/j.ejca.2019.05.019